Samarbetet mellan Wacker Biotech och Metheresis: ESETEC ® ökar utbytet av Mv-DN30, ett anti-MET antikroppsfragment för att bekämpa cancer
Om översättning önskas till svenska, kontakta marie-louise.kaervedal@wacker.com Munich/Jena, January 13, 2013 – Wacker Biotech and Metheresis Translational Research, a biotech company of the Italian phar-maceutical group Sigma-Tau, have reached a major milestone in their collaboration on the production of Metheresis’ drug candi-date Mv-DN30, an anti-MET Fab antibody fragment. With the aid of ESETEC®, WACKER's proprietary secretion technology, WACKER has developed an efficient cell line for the production of Mv-DN30. A study has shown that E. coli-based ESETEC® is capable of delivering much